Michael Duruisseaux Anne-Marie Dingemans eBioMedicine – The Lancet Discovery Science OncoAlert Short but highly changing practice study. IO to sotorasib therapeutic sequence needs : i) at least 6 weeks therapeutic IO hollydays; ii) eventually chemotherapy bridging treatment; iii) IO plasma concentration monitoring (or PD1 lymphocyte binding) before sotorasib introduction

📖 Anne-Marie Dingemans et al report on two cases demonstrating that osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance ➡️ brnw.ch/21wGr1y

This was a team effort! 🙏 Nicolas Alcala Matthieu Foll Lynnette Fernandez-Cuesta Rare Cancers Genomics Jules Derks, MD, PhD Maastricht UMC+ Anne-Marie Dingemans @ErasmucMC Margot Tesselaar UMC Utrecht International The Netherlands Cancer Institute & many more! 🙏 also to new collaborators Jaume Capdevila Vall d’Hebron Institute of Oncology (VHIO) Justo P. Castaño 🔬🧬🧫#SinCienciaNoHayFuturo IMIBIC Pedro Rocha Hospital del Mar /11

Amazing proud to meet my #gametheory heroes Katerina Stankova TU Delft and Joel Brown Moffitt Cancer Center Erasmus MC #LCMS

#ESMO23 Dr. Tina Cascone presents the results from CheckMate 77T: a phase III trial of neoadjuvant nivolumab (or placebo) + chemotherapy, surgery, then adjuvant nivolumab or placebo for 1 year. Primary endpoint EFS (BICR). Median f/u here 25.4 months (9/2023 data lock). #LCSM

NET poster#2 deciphering TNE spectrum. A1 carcinoids occur mainly in female, higher age, with DIPNECH and display DLL3 expression. Anne-Marie Dingemans and Jules Derks. Might help to treat adequately these tumors. #ESMO23

Flaura-2: escalation from osi to osi + CT makes sense in pts with ‘hard to treat’ EGFRmut NSCLC: exon 21, brain mets, and probably if symptoms/high tumor burden since PS1 pts derive more benefit than PS0. ~5X more Gr3 AEs & no signal in OS: not obvious in all comers. #WCLC2023

This is the final consensus

Today #WCLC23 we presented our consensual definition on stIII NSCLC resectability, to be used in clinical trials. A great multidisciplinary effort initiated by EORTC in joint collaboration with ESTS ERS ESTRO ETOP IBCSG Partners Foundation IASLC European Society of Pathology (ESP) #LCSM Erasmus MC

Don't miss the Oral session at 3 pm today at Summit 1 (level 3) w/ the #survey & the #consensus definition on stage III #NSCLC resectability by EORTC & other societies 🚨🫁
#wclc23 ETOP IBCSG Partners Foundation IASLC ESTRO ESTS #esp OncoAlert

😿RIP youtu.be/KKXewWDh1og

Drew Moghanaki 🐕 Jeff Bradley, MD What is the definition of “Unresectable” in the IO era? Very Important work pertinent to trial design and interpretation incoming IASLC #WCLC2023 from the EORTC Lung Group with leadership from Mariana Brandao & Anne-Marie Dingemans & many others

It's not possible to share this virtually. Thank you Marina Garassino for this amazing evening in Chicago

We love our #ASCO23 host Marina Garassino! Enriqueta Felip Solange Peters Delvys Rodriguez Abreu Lizza Hendriks Heather Wakelee arsela prelaj Claudia rossanaberardi Giulia pasello Luis Paz-Ares Martin Reck Noemi Reguart Anne-Marie Dingemans Christian Rolfo Justin Gainor d.planchard charocampelo

New kid in the block 🎯of NEO CT+IO in resectable NSCLC.After nivo, durva, and toripalimab, pembrolizumab arrives
Similar outcome!! 70% receive ADJ!!pending 🥶what patient could deescalate ADJ treatment? How to test pCR before surgery? Is it surgery necessary if pCR? #ASCO2023

Any discussion about #Stage3 #NSCLC #LungCancer is always stimulating: the EORTC Lung Group delivers an excellent appraisal of the current evidence & the optimal strategy for future trials. #LCSM

E Ruffino & D De Ruysscher on the pros&cons of #Surgery & #RadiationOncology for Stage III #NSCLC during the EORTC Lung Cancer Group symposium:
🔵 Always discuss in a MDT!
🔵 No evidence of ⬆️of 1 tx over the other
🔵 Clear definition of resectability is needed!
OncoAlert

Our @eortc lung cancer Young and Early Career Investigators masterclass started with an introduction by our president WinetteVanDerGraaf ! Great to host all these members from all over Europe. Erasmus MC

Friday May 12th the EORTC LCG organizes a symposium 're-defining stage III NSCLC'. Registration and program
eventure-online.com/eventure/login…
Sanjay Popat Jordi Remon Benjamin Besse Egbert Smit Mariana Brandao prof Joachim Aerts Egesta Lopci Erasmus MC

#Alectinib is used to treat patients who have metastatic #NSCLC w/an anaplastic lymphoma kinase ( #ALK ), but it may increase obesity & lead to serious metabolic/physical/mental issues in long-surviving patients. bit.ly/410QFKL #LCSM Anne-Marie Dingemans